Recursion Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Recursion Pharmaceuticals has a total shareholder equity of $463.4M and total debt of $1.1M, which brings its debt-to-equity ratio to 0.2%. Its total assets and total liabilities are $653.7M and $190.3M respectively.
Key information
0.2%
Debt to equity ratio
US$1.14m
Debt
| Interest coverage ratio | n/a |
| Cash | US$391.57m |
| Equity | US$463.44m |
| Total liabilities | US$190.26m |
| Total assets | US$653.70m |
Recent financial health updates
Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31
We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth
Mar 01Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Can Afford To Invest In Growth
Jul 25Recent updates
Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today
May 09We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth
Mar 01Recursion Pharmaceuticals: Destination Unknown
Sep 20Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Can Afford To Invest In Growth
Jul 25Recursion gets European orphan drug designation for its REC-4881 inhibitor
Jul 21These Analysts Think Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Sales Are Under Threat
May 16Recursion Pharmaceuticals, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 14Financial Position Analysis
Short Term Liabilities: RXRX's short term assets ($438.1M) exceed its short term liabilities ($93.2M).
Long Term Liabilities: RXRX's short term assets ($438.1M) exceed its long term liabilities ($97.1M).
Debt to Equity History and Analysis
Debt Level: RXRX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if RXRX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RXRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RXRX has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 40.8% each year.